Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “CTOR”

756 pharma patents match "CTOR" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 756
Index total 30,257
Page 9 / 32

Quick answer

This filtered view shows 756 pharmaceutical patents matching "CTOR" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

756 results for “CTOR” · 30,257 patents in full index Clear search

  1. US 11028444

    Survival predictor for diffuse large B cell lymphoma

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted
  2. US 11020458

    Factor VIII polymer conjugates

    Takeda Pharmaceutical Company Limited · Granted Jun 1, 2021 · Expires May 27, 2041

    granted
  3. US 11020459

    Factor VIII formulations

    UNIVERSITY OF CONNECTICUT · Granted Jun 1, 2021 · Expires May 27, 2041

    granted
  4. US 11014980

    Transforming growth factor-beta-responsive polypeptides and their methods for use

    The Regents of the University of California · Granted May 25, 2021 · Expires May 20, 2041

    granted
  5. US 11007201

    Corticotropin releasing factor receptor antagonists

    SPRUCE BIOSCIENCES, INC. · Granted May 18, 2021 · Expires May 13, 2041

    granted
  6. US 10993999

    Materials and methods for producing improved lentiviral vector particles

    IMMUNE DESIGN CORP. · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  7. US 10988733

    Methods for obtaining pluripotent adult olfactory stem cells from an olfactory mucosa tissue

    China Medical University · Granted Apr 27, 2021 · Expires Apr 22, 2041

    granted
  8. US 10982203

    Modified factor IX polypeptides and uses thereof

    Catalyst Biosciences, Inc. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  9. US 10982001

    Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Five Prime Therapeutics, Inc. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  10. US 10975153

    Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Five Prime Therapeutics, Inc. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted
  11. US 10968442

    Chimeric clotting factors

    BIOVERATIV THERAPEUTICS INC. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  12. US 10954530

    Retroviral and lentiviral vectors

    AUTOLUS LIMITED · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted
  13. US 10934544

    Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted
  14. US 10927346

    Enhanced immune effector cells and use thereof

    Fate Therapeutics, Inc. · Granted Feb 23, 2021 · Expires Feb 18, 2041

    granted
  15. US 10918738

    Method of treating type I diabetes using an AAV vector encoding uracortin 2

    The Regents of the University of California · Granted Feb 16, 2021 · Expires Feb 11, 2041

    granted
  16. US 10898554

    Factor IX polypeptides and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Jan 26, 2021 · Expires Jan 21, 2041

    granted
  17. US 10894966

    Virus-based expression vectors and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 19, 2021 · Expires Jan 14, 2041

    granted
  18. US 10881742

    Factor VIII chimeric and hybrid polypeptides, and methods of use thereof

    BIOVERATIV THERAPEUTICS INC. · Granted Jan 5, 2021 · Expires Dec 31, 2040

    granted
  19. US 10883107

    Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jan 5, 2021 · Expires Dec 31, 2040

    granted
  20. US 2020384125

    GENE EDITING FOR HEMOPHILIA A WITH IMPROVED FACTOR VIII EXPRESSION

    CRISPR THERAPEUTICS AG [CH] · Granted Dec 10, 2020 · Expires Dec 5, 2040

    granted
  21. US 10858658

    Compositions and methods for inhibiting gene expression of factor XII

    Arrowhead Pharmaceuticals, Inc. · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  22. US 10849908

    Corticotropin releasing factor receptor antagonists

    SPRUCE BIOSCIENCES, INC. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  23. US 10822421

    Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    Five Prime Therapeutics, Inc. · Granted Nov 3, 2020 · Expires Oct 29, 2040

    granted
  24. US 10813913

    Small molecules that mimic or antagonize actions of granulocyte colony-stimulating-factor (G-CSF)

    United States Government as represented by the Department of Veterans Affairs · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted